-Impairment of skeletal muscle function has been associated with changes in ovarian hormones, especially estradiol. To elucidate mechanisms of estradiol on skeletal muscle strength, the hormone's effects on phosphorylation of the myosin regulatory light chain (pRLC) and muscle contractility were investigated, hypothesizing an estradiol-specific beneficial impact. In a skeletal muscle cell line, C 2C12, pRLC was increased by 17␤-estradiol (E 2) in a concentration-dependent manner. In skeletal muscles of C57BL/6 mice that were E 2 deficient via ovariectomy (OVX), pRLC was lower than that from ovary-intact, sham-operated mice (Sham). The reduced pRLC in OVX muscle was reversed by in vivo E 2 treatment. Posttetanic potentiation (PTP) of muscle from OVX mice was low compared with that from Sham mice, and this decrement was reversed by acute E 2 treatment, demonstrating physiological consequence. Western blot of those muscles revealed that low PTP corresponded with low pRLC and higher PTP with greater pRLC. We aimed to elucidate signaling pathways affecting E 2-mediated pRLC using a kinase inhibitor library and C 2C12 cells as well as a specific myosin light chain kinase inhibitor in muscles. PI3K/Akt, MAPK, and CamKII were identified as candidate kinases sensitive to E 2 in terms of phosphorylating RLC. Applying siRNA strategy in C 2C12 cells, pRLC triggered by E 2 was found to be mediated by estrogen receptor-␤ and the G protein-coupled estrogen receptor. Together, these results provide evidence that E 2 modulates myosin pRLC in skeletal muscle and is one mechanism by which this hormone can affect muscle contractility in females. estrogen; estrogen receptor; kinase; post tetanic potentiation; RLC OVARIAN HORMONE DEFICIENCY is related to muscle dysfunction and loss of strength. For example, declines in strength are accelerated around the time of menopause (35, 41, 51) , and skeletal muscles of postmenopausal women on estrogen-based hormone therapy are stronger than those not on hormone therapy (10, 17, 49) . In mouse models, contractile characteristics are impaired in muscles of ovariectomized compared with sham-operated mice (16, 38, 39, 53, 65) . It was suggested (41) and subsequently demonstrated that ovarian hormones influence muscle strength by directly affecting the function of contractile proteins (43, 66) , particularly the structure and function of myosin (38, 39) . Among the ovarian hormones, 17␤-estradiol (E 2 ) appears to be the key hormone, because it reverses muscle weakness and contractile protein dysfunction caused by ovariectomy. Specifically, reduced muscle and contractile protein functions were restored when E 2 was administered to ovariectomized mice (16, 38, 53) . In a chemical model of premature aging, of which the ovaries of young adult mice were locally and specifically induced to be senescent, E 2 treatment improved some muscle contractile functions (18) . Although these studies have demonstrated that E 2 impacts muscle and myosin functions, the molecular mechanisms by which this hormone affects the structure and function of myosin, and thus strength, remain to be elucidated.
with sham-operated mice (16, 38, 39, 53, 65) . It was suggested (41) and subsequently demonstrated that ovarian hormones influence muscle strength by directly affecting the function of contractile proteins (43, 66) , particularly the structure and function of myosin (38, 39) . Among the ovarian hormones, 17␤-estradiol (E 2 ) appears to be the key hormone, because it reverses muscle weakness and contractile protein dysfunction caused by ovariectomy. Specifically, reduced muscle and contractile protein functions were restored when E 2 was administered to ovariectomized mice (16, 38, 53) . In a chemical model of premature aging, of which the ovaries of young adult mice were locally and specifically induced to be senescent, E 2 treatment improved some muscle contractile functions (18) . Although these studies have demonstrated that E 2 impacts muscle and myosin functions, the molecular mechanisms by which this hormone affects the structure and function of myosin, and thus strength, remain to be elucidated. E 2 affects multiple signaling pathways via both genomic and nongenomic manners. While two estrogen receptors (ERs), ER␣ and ER␤, had originally been shown to exist in skeletal muscle, a third ER, the G protein-coupled receptor (GPER), has also been identified in skeletal muscles (2, 5) . An important molecular event in these signaling pathways mediated by E 2 involves the downstream regulation of transcription by the ERs. For example, ERs have been implicated in the regulation of gene transcription in myoblasts, including kinases that regulate GLUT4, myogenin, and myosin heavy chain expression (12) . E 2 is also an important molecule activating several kinases and kinase cascades, such as phosphatidylinositide 3-kinase/Akt (PI3K/Akt), MAPK, and AMP-activated protein kinase (AMPK), in a multitude of cells and tissues including skeletal muscle (46, 48, 68) . These cellular processes result in altered kinase activity and thus protein phosphorylation. Since protein phosphorylation is one critical regulatory event that can affect muscle contractility (e.g., Ref. 55) , we postulated that E 2 exerts its impact on muscle and myosin functions by regulating protein phosphorylation events, particularly those occurring on contractile proteins such as myosin.
Myosin belongs to a superfamily of motor proteins and in striated muscle consists of two heavy chains and two pairs of light chains, the essential light chain and the regulatory light chain (RLC). While the essential light chain is considered to play a role in stabilizing the overall structure of myosin, the RLC acts as a lever arm on the ␣-helical neck region of the myosin heavy chain to transmit free energy of ATP hydrolysis down the neck domain to amplify movements of myosin and force production during contraction (44) . Ser 15 of the RLC can be phosphorylated by myosin light chain kinase (MLCK) (59) , and other kinases, such as Rho-associated kinase (ROCK) and ERK1/2, may also phosphorylate serine or threonine sites of the RLC (1, 20) . When RLC is not phosphorylated, the light chain domain of myosin is positioned close to the thick filament backbone (67, 71) . However, when phosphorylated, the light chain domain projects from the thick filament backbone so that myosin heads are better positioned to bind actin thin filament and initiate the power stroke (6, 28, 36) . Thus, by undergoing phosphorylation, RLC modulates myosin structure, molecular force generation, and power output of striated muscle (6, 69) . RLC phosphorylation (pRLC) is such a critical mechanism in the heart that specific mutations that disrupt the phosphorylation of RLC in cardiac myosin reduce force and cause cardiomyopathy (15, 40, 55) .
In mouse cardiomyocytes, E 2 plays a role in regulating pRLC, which correlates with contractility of those cells (24, 25) . Here, we hypothesized that E 2 improves skeletal muscle and myosin functions by increasing pRLC. We examined the related cellular pathways mediated by E 2 on pRLC, as well as the effects on force generation. We present data demonstrating that E 2 mediates phosphorylation of the myosin RLC in skeletal muscle through ER␤ and GPER and several kinases, including PI3K, MAPK, and Ca 2ϩ /calmodulin-dependent protein kinase II (CamKII). Our results show that the biochemical effect of phosphorylating RLC by E 2 in skeletal muscle has a physiological impact on contractility.
MATERIALS AND METHODS
Reagents. Sources for reagents were: 17␤-E2 (Sigma, St. Louis, MO); ML-7 (Tocris Bioscience, Bristol, UK); Screen-Well kinase inhibitor library (Enzo Life Sciences, Farmingdale, NY); phosphatase inhibitor cocktail II and III (P5726 and P0044, respectively, Sigma); Complete, Mini, EDTA-free protease inhibitor cocktail (Roche; Sigma); antibodies to ER␣ and ER␤ (F3-A and 68-4, respectively; Millipore, Billerica, MA), GAPDH (ab9485; Abcam, Cambridge, MA), phosphorylated RLC and RLC (ab2480 and ab48003, respectively, Abcam); control siRNA, ER␣ siRNA, ER␤ siRNA, and GPER siRNA (Dharmacon, Layfayette, CO); HiperFect transfection reagent (Qiagen, Valencia, CA); DMEM (GIBCO, Grand Island, NY); fetal bovine serum and penicillin-streptomycin (Invitrogen, Grand Island, NY); TRIzol Reagent (Thermo Fisher Scientific, Grand Island, NY). All components of the Krebs-Ringer bicarbonate buffer for the in vitro muscle preparation were from Sigma.
Cell culture. C 2C12 muscle cells were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, at 37°C in 5% CO 2. One day before experiments, cells were plated onto six-well dishes and 24 h later were 70 -80% confluent. Prior to E2 treatment, cells were washed once with 1ϫ PBS and incubated in DMEM containing no serum (serum deprivation) for 30 min. 17␤-E 2 dissolved in isopropanol or vehicle control (i.e., isopropanol only) was added to cells and cells were incubated for 30 min in the incubator. Cells were then immediately lysed in ice-cold NP-40 lysis buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 1% NP-40), containing protease inhibitor and phosphatase inhibitor II and III cocktails. This lysate was centrifuged and the supernatant used for Western blotting.
For siRNA knockdown experiments, cells were plated onto sixwell plates and transfected with control siRNA or ER isoform-specific siRNA using HiperFect transfection reagent according to the manufacturer's fast-forward protocol. Cells were lysed 48 or 72 h after transfection in NP-40 lysis buffer as described above.
For kinase inhibitor experiments, C 2C12 cells were plated onto six-well plates at a cell confluence of 70 -80%. Seventy of the eighty kinase inhibitors from the kinase inhibitor library were tested (10 that were not tested were those known to be nonspecific). Each inhibitor was individually dissolved in DMSO as a 10 mM stock solution. Inhibitor ϩ E 2 or DMSO ϩ E2 were applied to cells for a final concentration of 10 M inhibitor (27) and 1 M E 2. The selective MLCK inhibitor ML-7 was also tested at 40 M. The final concentration of DMSO in the cell culture medium was Յ0.5% (vol/vol). Cells were incubated for 30 min at 37°C with 5% CO 2. Cells were lysed in NP-40 as described and then used for Western blotting to determine pRLC and total RLC. All cell experiments were carried out in phenol red-free medium and done in triplicate.
Animals. Female C57BL/6 mice aged 3-4 mo were purchased from the National Institute on Aging or were bred on site. Mice underwent bilateral ovariectomy surgeries (OVX) or sham operations (Sham), which consisted of the same procedures as the OVX except that the ovaries were not removed. For some experiments, subgroups of OVX mice immediately received E 2 treatment (OVXϩE2) via 60-day time release pellets, as described previously (38) . Muscles from mice were studied 4 -6 wk postsurgery, except for a subgroup of Sham and OVX mice that were studied 5 mo after surgeries in one experiment (detailed in legend of Fig. 3 ). On the day of euthanasia, mice were anesthetized by injection of pentobarbital sodium (100 mg/kg body mass ip), and muscles were dissected. Uteri were dissected and weighed as an indicator of successful ovariectomy surgery or E2 replacement [mean Ϯ SD uterine mass for Sham, OVX, OVXϩE2: 107.4 (37.2), 14.0 (3.7), and 136.3 (83.6) mg, respectively]. While under anesthesia, mice were euthanized by exsanguination. All protocols were approved by the Institutional Animal Care and Use Committee at the University of Minnesota and complied with the American Physiological Society guidelines.
In vitro contractility and posttetanic potentiation. Extensor digitorum longus (EDL) or soleus muscles were dissected and mounted in a 1.5-ml bath assembly containing Krebs-Ringer bicarbonate buffer maintained at 25°C. The proximal tendon was connected by 5-0 silk suture to the arm of a muscle lever system (300B-LR; Aurora Scientific, Aurora, ON, Canada), while the distal tendon was tied by suture and stabilized so that no movement occurred. Muscles were preincubated for 30 min prior to any contractile activity. During this time, optimal muscle length was maintained by keeping resting tension at 0.4 or 0.5 g for EDL and soleus muscles, respectively (63, 64) . For experiments investigating MLCK's involvement in RLC phosphorylation by E2, the selective MLCK inhibitor ML-7 at 25 M for EDL and 2 M for soleus or an equal volume of ethanol vehicle was added to the Krebs buffer during the 30-min preincubation. A subgroup of muscles was incubated with ML-7 for 30 min, and then 1 M E2 was added for 30 min and posttetanic potentiation (PTP) was measured. For experiments testing the acute presence of E2 on PTP of EDL muscles, 1 M E2 was added to the Krebs buffer during the 30-min preincubation prior to PTP contractions.
The PTP protocol for EDL muscles was adapted from Stull et al. (70) . Following the 30-min preincubation, a baseline isometric twitch was elicited by stimulating the muscle with a 0.5-ms pulse at 150 V (S48 with SIU5D stimulus isolation unit; Grass Technologies, Warwick, RI). Three twitches were performed with 1-min rest in between each pulse. The muscle was then stimulated at 150 Hz and 150 V for 2,000 ms to produce a prolonged, isometric tetanic contraction. Fifteen seconds following the tetanic contraction, the posttetanic twitch was elicited. PTP was calculated as the percent increase in force from the baseline twitch (the greatest of the three initial twitches) to the posttetanic twitch. The maximal rate of force devel-opment (ϩdP/dt) from these same twitches were determined, and the percent increase was calculated from the baseline to the posttetanic twitch.
For soleus muscle, there is minimal potentiation of twitch force (Ͻ10%) elicited by the EDL PTP protocol or variations of that protocol (50, 60) , and in preliminary experiments we found the same. Because it would be difficult to detect attenuation from this already low level of potentiation, we developed a tetanic potentiation protocol for soleus muscles based on the concept 1) of staircase potentiation (60), only using a higher stimulation frequency to elicit tetanic rather than twitch contractions; 2) that high stimulation frequency is needed to phosphorylate RLC in soleus muscle (37); 3) that soleus muscle is fatigue resistant and can endure repetitive, long-duration stimulations during the potentiating contractions without run down; and the knowledge 4) that stronger stimulus factors such as concentric force and work modulate the extent of potentiation (69) . Thus, for soleus muscle the potentiating contractions were elicited through a series of maximal isometric tetanic contractions, again following a 30-min preincubation. Specifically, soleus muscles were stimulated at 120 Hz and 150 V for 400 ms every 2 min until the peak force produced during those contractions plateaued, which typically occurred at eight contractions. Tetanic potentiation (increase in P o) was calculated as the percent increase in force from the first to final tetanus.
EDL and soleus muscles were quickly removed from the bath assembly after potentiation protocols and frozen within 20 s of the final contraction (69) . Muscles were stored at Ϫ80°C until examined by Western blot for total RLC and pRLC.
Western blots. Mouse EDL or soleus muscles were homogenized in NP-40 lysis buffer containing protease inhibitor and phosphatase inhibitor II and III cocktails, using bullet blender according to the manufacturer's instructions (Midwest Scientific, St. Louis, MO). Homogenates were centrifuged at 664 g for 10 min at 4°C to remove connective tissue. The supernatant containing myofilaments was collected, and protein concentrations were determined. Loading buffer was added to these protein lysates or to the C2C12 cell lysates and were loaded on SDS-PAGE gels. Following electrophoresis, proteins were transferred to nitrocellulose membranes and probed for ER␣, ER␤, or pRLC for either 2.5 h at room temperature or overnight at 4°C. Membranes were washed, incubated with a secondary antibody for 1 h, washed, and then scanned and quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). Blots initially probed for pRLC or ER were stripped and reprobed for total RLC or GAPDH, respectively. Under circumstances when stripping was not possible or successful, duplicate gels of the same lysate were run, e.g., one gel for pRLC and the other gel for total RLC.
The Abcam RLC and pRLC antibodies we used were generated against myosin RLC isoforms found in smooth and cardiac muscle and nonmuscle cells, according to Abcam product information. In preliminary experiments, we tested these antibodies, as well as several other commercially available RLC antibodies, for cross-reactivity to skeletal muscle RLC. For this, we used purified myosin (33) and permeabilized, isolated skeletal muscle fibers from rabbit and mouse muscle (7) . Figure 1 shows cross-reactivity of the Abcam RLC and pRLC antibodies to skeletal muscle RLC similar to that reported by others (20) , and also shows sensitivity to phosphorylated and dephosphorylated conditions (7, 58) . Because there is expected to be minimal to no smooth or cardiac RLC in purified skeletal muscle myosin or in single skeletal muscle fibers, the strong bands detected are skeletal muscle RLC and demonstrate specific cross-reactivity of these antibodies. Furthermore, we had previously confirmed that this standard protocol for rendering permeabilized skeletal muscle with either dephosphorylated or phosphorylated RLC and the Western blot pRLC antibody detection method yielded results consistent with pRLC detection methods using isolated striated muscle fibers (6, 58) .
qPCR. RNA from C2C12 cells was isolated using TRIzol Reagent according to the manufacturer's instructions. cDNA was synthesized from 1 g of RNA according to directions in the VILO cDNA Synthesis Kit. Relative quantitation of the GPER transcript was determined using SYBR Green Master Mix and the following primers for GPER (forward TTCCTCACCTGGATGAGCTT; reverse CCT-GACATCAGCAAAGCAGA).
Statistical analysis. Data are expressed as means Ϯ SE. Statistical analyses were done by Student's t-tests or one-way ANOVAs. Twoway ANOVAs were used to determine the effect of E2 vs. vehicle on PTP and pRLC of OVX vs. Sham muscles. When a significant main effect or interaction was detected, Holm-Sidak post hoc tests were done. All statistics were performed using SigmaStat 12.0 (Systat Software, San Jose, CA) with significance accepted at P Ͻ 0.05.
RESULTS

RLC phosphorylation is affected by E 2 in skeletal muscle cells and skeletal muscle.
To determine if RLC phosphorylation in skeletal muscle cells is responsive to E 2 , C 2 C 12 cells were treated with various concentrations of E 2 for 30 min. As shown in Fig. 2A , phosphorylation of the pRLC was increased by E 2 treatment in a concentration-dependent manner (P ϭ 0.005). Total RLC remained unchanged across the E 2 concentrations (P ϭ 0.180).
To support this finding with in vivo data, pRLC was measured and found to be different in skeletal muscles from female mice with and devoid of ovarian hormone production (P ϭ 0.014; Fig. 2B ). pRLC was ϳ35% lower in EDL muscles from OVX mice compared with Sham mice; however, in vivo treatment of OVX mice with E 2 restored pRLC levels to those of Sham mice. Therefore, the decrement in RLC phosphorylation can be attributed to the hormone E 2 . Similar results were found in soleus muscles, with pRLC in OVX mice being ϳ50% lower than that from Sham and OVXϩE 2 mice (P Յ 0.016). Total RLC content did not differ among muscles from these three groups of mice for either EDL or soleus muscle (P Յ 0.143). Together, these in vitro cell culture and in vivo muscle data demonstrate that RLC phosphorylation in skeletal muscle is affected by the surrounding E 2 levels. E 2 -mediated RLC phosphorylation impacts muscle contractility. To determine the extent to which RLC phosphorylation mediated by E 2 results in a functional consequence, EDL muscles were dissected from Sham and OVX mice and studied in vitro for PTP (Fig. 3, A and B) . Peak force of the unpotentiated, baseline twitches were not different between Sham and OVX mice (56.2 Ϯ 2.3 and 54.1 Ϯ 2.7 mN, respectively, P ϭ 0.405). Potentiated twitches generated 25-50% more force than unpotentiated twitches; however, the extent of PTP depended on the presence of E 2 ( Fig. 3C ; interaction P ϭ 0.046). In particular, PTP of vehicle-incubated EDL muscles was more than two times greater in those from Sham than OVX mice (51.6 Ϯ 6.7 vs. 24.1 Ϯ 7.1% increase, P ϭ 0.009; Fig. 3C ), indicating that the chronic deficiency of circulating E 2 negatively impacts muscle force potentiation. Acute exposure of muscles from OVX mice to E 2 in the bath resulted in greater PTP (P ϭ 0.036; Fig. 3C ). EDL muscles that were chronically exposed to endogenous E 2 (Sham mice) had relatively high PTP regardless of vehicle or E 2 in the bath.
The maximal rate of force development (ϩdP/dt) by EDL muscles during unpotentiated twitches did not differ between Sham and OVX mice (6.41 Ϯ 0.44 and 6.73 Ϯ 0.58 N/s, respectively, P ϭ 0.656). Relative to unpotentiated twitches, muscles from Sham mice developed force faster during the potentiated twitches compared with those from OVX mice ( Fig. 3D ; main effect of mouse group, P Ͻ 0.001). Notably, the increase in ϩdP/dt was greater in E 2 -vs. vehicle-incubated EDL muscles (main effect of treatment, P Ͻ 0.001) regardless of whether the muscle came from a mouse that had a sham or ovariectomy surgery (interaction P ϭ 0.183). These results are consistent with enhanced contractility with chronic and acute exposure to E 2 , and diminished contractility with deficiency of E 2 . For each measure (i.e., PTP, ϩdP/dt, and pRLC, below), there was no difference between mice that were ovariectomized at 4 -6 wk and those that were ovariectomized for 5 mo; P Յ 0.527).
Previous studies have shown that RLC phosphorylation is the primary mechanism for PTP (59) . To confirm that the E 2 -mediated PTP effects in EDL muscles were related to RLC phosphorylation, those muscles were analyzed for pRLC content. Similar to the E 2 effects on PTP, the level of pRLC in EDL muscles depended on the presence of E 2 (interaction P ϭ 0.048; Fig. 4) . pRLC of vehicle-incubated EDL muscles from OVX mice was about one-half of that from Sham mice. Acute exposure of muscles from OVX mice to E 2 rescued pRLC (Fig.  4) . In muscles from Sham mice, acute exposure to E 2 did not affect pRLC. Thus, these biochemical events parallel the physiological effects indicating that E 2 's impact on PTP is consistent with an E 2 -induced effect on phosphorylation of the RLC.
RLC phosphorylation by E 2 is mediated by ER␤ and GPER in muscle cells. Next, we aimed to elucidate which receptor is responsible for mediating the phosphorylation of RLC by E 2 . To do this, siRNA strategy was applied to C 2 C 12 cells treated with E 2 . Transfection of siRNA for ER␣ significantly reduced ER␣ protein to 34% compared with control siRNA (P ϭ 0.006; Fig. 5A ). However, pRLC of cells exposed to E 2 was not affected (P ϭ 0.868; Fig. 5A ). In contrast, siRNA specific for ER␤ not only resulted in decreased ER␤ expression to ϳ70% of its control, but it also attenuated E 2 -induced pRLC by a similar extent (P Յ 0.041; Fig. 5B ). Because we were not able to identify a quality commercially available antibody that is specific for GPER, successful knockdown of GPER by siRNA was confirmed by measuring its mRNA level by qPCR. siRNA specific for GPER reduced its mRNA level to 47% of control with a simultaneous reduction on pRLC (P Յ 0.023; Fig. 5C ). Together, these data suggest that E 2 -induced phosphorylation of the RLC in skeletal muscle cells is mediated through ER␤ and GPER, but not ER␣.
E 2 -induced RLC phosphorylation is mediated by MLCK in EDL but not soleus muscle. Our findings raise the question as
to what downstream signaling pathway(s) is/are activated by E 2 and the ERs to phosphorylate RLC. We hypothesized that kinase cascade(s) downstream of ER␤ and GPER affect(s) RLC phosphorylation and consequently muscle contractility. As MLCK is known to directly phosphorylate RLC in muscle, we first focused on that kinase in EDL muscle from ovaryintact mice. As shown in Fig. 6A , PTP was 51% lower in EDL muscles exposed to 25 M ML-7, a specific MLCK inhibitor (P ϭ 0.018). Exposure of EDL muscle to E 2 after ML-7 incubation did not rescue the inhibitory effect of ML-7. Biochemically, ML-7 decreased pRLC to ϳ50% of that in the control, vehicle-treated EDL muscles regardless of E 2 's presence in the bath (P ϭ 0.003; Fig. 6B ). Thus, these biochemical data are consistent with the physiological results, further supporting the role of pRLC by E 2 in muscle force potentiation. Importantly, these results imply that in EDL muscle the effect of E 2 on phosphorylation of the RLC is dependent on MLCK activity. Next, we addressed the same question using soleus muscle, because there are known differences in the extent to which MLCK and pRLC affect the potentiation of force between EDL and soleus mouse muscles (50) . Using the tetanic potentiation protocol we developed, Fig. 7 shows that tetanic force was potentiated by 18.7 Ϯ 1.6% in soleus muscle (Veh; Fig. 7 , A and C), and RLC was phosphorylated (Fig. 7D, Veh) . When the same 25 M concentration of ML-7 was used on isolated soleus muscles in preliminary experiments, tetanic force was substantially impaired. Reducing ML-7 to 2 M resulted in normal tetanic force generation so that its inhibitory effects on potentiation could be investigated. Relative to vehicle control, tetanic force potentiation in soleus muscle was halved when Fig. 3 . E2 improves EDL muscle potentiation of force and maximal rate of force development (ϩdP/dt). A: representative unpotentiated and potentiated twitch force tracings by isolated EDL muscles from Sham and OVX mice. Potentiated twitch force was greater in EDL muscles of Sham than of OVX mice. B: representative twitch force tracings of isolated EDL muscles from OVX mice acutely exposed to vehicle (Veh) or E2 in the bath. Potentiated twitch force was greater in EDL muscles when E2 was added to the experimental bath compared with adding only vehicle. C: acute exposure of EDL muscles from Sham mice to E2 in the bath did not affect posttetanic potentiation (PTP). PTP was low in EDL muscles from mice chronically deficient in E2 (OVXϩVeh), which was rescued by 30-min incubation in E2 (OVXϩE2). D: ϩdP/dt was faster in EDL muscles chronically exposed to circulating E2 (Sham mice) and in those acutely exposed to E2 in the bath; n ϭ 5-8 muscles per group for C and D. Within Sham, n ϭ 8 mice 4 -6 wk postsurgery and n ϭ 6 mice 5 mo postsurgery; within OVX, n ϭ 8 mice 4 -6 wk postsurgery and n ϭ 7 mice 5 mo postsurgery. P Ն 0.527 comparing data from 4 -6 wk and 5 mo postsurgery groups; therefore, those data were combined (to obtain the 5-8 muscles/group). Data are means Ϯ SE. *Significantly different from 3 other groups; $E2 groups significantly different from Veh groups; #OVX groups significantly different from Sham groups. exposed to ML-7, down to only 9.8 Ϯ 1.7, (Fig. 7 , B and C; P ϭ 0.010). This inhibitory effect was accompanied by a corresponding reduction in pRLC (P ϭ 0.002; Fig. 7D ). Exposure of soleus muscle to E 2 following the ML-7 treatment rescued both physiological and biochemical inhibitory effects (Fig. 7, C and D) , suggesting that E 2 augments pRLC in soleus muscle without a dependence on MCLK. Thus, these data provide evidence that phosphorylation of the RLC mediated by E 2 in soleus muscle can occur through another kinase or kinase cascade in addition to MLCK.
Kinase cascades regulating E 2 -mediated RLC phosphorylation. To further identify possible kinase/kinase cascades involved in RLC phosphorylation by E 2 beyond MLCK, a library containing inhibitors specific for various known kinases was used. C 2 C 12 cells were treated with E 2 alone or E 2 combined with inhibitor, and the consequent pRLC in the cellular lysate was assessed by Western blot. Results are summarized in Table 1 , showing that 11 specific inhibitors attenuated pRLC triggered by E 2 . The inhibition ranged from 13 to 38% relative to the cells treated with E 2 alone (control condition). Affected kinases included CamKII and ROCK. Together, these data provide mechanistic insight into other kinase cascades affecting the E 2 -induced phosphorylation of the RLC.
DISCUSSION
E 2 impacts skeletal muscle contractility, and here we tested the hypothesis that an underlying mechanism involves E 2 -dependent posttranslational modification of a contractile pro- Fig. 6 . PTP and corresponding pRLC of EDL muscle by E2 exposure depend on active myosin light chain kinase (MLCK). A: PTP was reduced by half with exposure of EDL muscles to MLCK inhibitor ML-7 in bathing medium. The reduction was not reversed by subsequent exposure to E2 (ML-7ϩE2). B: pRLC was decreased by ML-7 and, similarly to PTP, E2 exposure did not reverse the inhibitory effect. These experiments were conducted on muscles from ovary-intact female mice. Data are means Ϯ SE; n ϭ 6 per condition. Error bars are within mean bars for some data. *Significantly different from Veh. Fig. 5 . Modulation of pRLC by E2 is mediated by estrogen receptor (ER)␤ and G protein-coupled ER (GPER), but not ER␣, in C2C12 cells. A: representative Western blots show depletion of ER␣ by siRNA and the corresponding effect on pRLC. ER␣ was determined relative to GAPDH and pRLC relative to total RLC. siRNA mediated downregulation of ER␣ in C2C12 cells but did not affect pRLC. B: representative Western blots show reduction of ER␤ by siRNA and the corresponding effect on pRLC. ER␤ was determined relative to GAPDH and pRLC relative to total RLC. Knockdown of ER␤ by siRNA resulted in a decrease in pRLC. C: qPCR analysis indicated a significant reduction of GPER mRNA by siRNA, and the corresponding effect on pRLC is shown by Western blot. GPER mRNA was determined relative to GAPDH mRNA. pRLC relative to total RLC protein is shown. Reduced GPER by siRNA resulted in decreased pRLC; n ϭ 3-4 per condition. *Significantly different from corresponding control siRNA.
tein. Our data support the hypothesis that E 2 induces phosphorylation of the myosin RLC and that in mouse hindlimb muscles there is a physiological consequence of increasing force generation. Our results also indicate that E 2 works through specific kinase signaling pathways involving ER␤ and GPER. These data extend previous reports of E 2 affecting skeletal muscle force generation (16, 38, 39, 43, 66) and provide insight into a specific molecular modification of myosin as an underlying mechanism. E 2 , as well as the estrogenic compound genistein, has previously been shown to enhance pRLC in other cell types including mouse cardiac muscle (24, 54) . Consistent with those results, the current study provides evidence that E 2 increased pRLC in a skeletal muscle cell line ( Fig. 2A) . Furthermore, whereas pRLC was decreased by ovarian hormone deficiency in skeletal muscle of OVX mice, E 2 treatment of OVX mice successfully rescued the decrement (Fig. 2B) . Collectively, these data provide evidence that E 2 enhances phosphorylation of the myosin RLC in skeletal muscle.
In skeletal muscle, pRLC increases the sensitivity of the actin-myosin contractile apparatus to Ca 2ϩ activation, thus enhancing myosin motor function and development of force (23, 36, 60) . Thus, we speculated that E 2 -induced pRLC has a functional impact on contractility. We tested our hypothesis by investigating PTP in isolated skeletal muscles, because pRLC induced the potentiation of force and the rate of force development (14, 59, 60) . Indeed, potentiated force and the maximal rate of force development (ϩdP/dt) were lower in EDL muscles from OVX than in Sham mice. These muscles also had low pRLC, suggesting that chronic deprivation of E 2 in skeletal muscle to E 2 perturbs contractility by low pRLC. The OVXinduced decrements on pRLC and PTP were rescued by acutely exposing isolated muscles to E 2 (OVXϩE 2 ; Figs. 3 and 4) . The long-term consequence of heightened PTP by E 2 -mediated pRLC is not clear, but because PTP regulates mechanical function of contracting skeletal muscle by augmenting Ca 2ϩ sensitivity of contractile apparatus to increase the development of force, it has been suggested that overall muscle performance could benefit (14, 60) . Theoretically, the nature of E 2 repetitive fluctuations in females could induce an adaptive response that would benefit muscle performance in the long term, although further studies will need to test this theory. Additional physiologically relevant effects of E 2 on muscle contractility include the hormone's impact on the myosin super-relaxed state (SRX) (7), which is also known to be regulated by phosphorylation of the RLC (58) , and the insulin signaling pathway to maintain glucose homeostasis (3) .
The effects of E 2 on muscle can be mediated by ERs through genomic or nongenomic actions of the hormone (4, 31) . The modulation of protein activity in the cytoplasm by nongenomic steroid mechanisms can be very rapid, on the time scale of Data are means Ϯ SE. E2, 17␤-estradiol; pRLC, phosphorylated myosin regulatory light chain. Compounds listed are those that inhibited pRLC Ͼ10% relative to E2 alone (control condition). Fig. 7 . Potentiation of tetanic force and corresponding pRLC of soleus muscle by E2 exposure do not require active MLCK. A: representative unpotentiated and potentiated isometric tetanic force tracings by isolated soleus muscles in Krebs buffer with vehicle added. Force is potentiated by ϳ20%. B: representative unpotentiated and potentiated isometric tetanic force tracings by isolated soleus muscles in Krebs buffer containing ML-7. Force is potentiated by only ϳ10% in the presence of the MLCK inhibitor. C: tetanic force potentiation (Po increase) was inhibited by ML-7, and, in contrast to EDL muscle (Fig. 6) , the inhibitory effect on force increase was reversed by exposure to E2. D: pRLC was decreased by ML-7 and, consistent with force potentiation, the reduction of pRLC by ML-7 in soleus muscle was rescued by E2. These experiments were conducted on muscles from ovary-intact female mice. Data are means Ϯ SE; n ϭ 4 per condition. *Significantly different from Veh.
seconds to minutes, and the resulting functions are often related to the activation of protein kinase cascades (30) . In the current study, phosphorylation of the RLC was increased in C 2 C 12 cells and in isolated muscles within 30 min of E 2 administration (Figs. 2 and 4) . Such an acute response suggests that a nongenomic mechanism of kinase activation by E 2 may be involved. However, in some circumstances, signaling pathways for genomic and nongenomic actions of E 2 on target genes can interact (4) , and E 2 has been shown to influence the expression of several members of the contractile apparatus in the heart, including myosin heavy chain, via direct gene regulation (25, 26) . Therefore, genomic mechanisms should not at this point be excluded, and additional studies are necessary to distinguish genomic vs. nongenomic ER mechanisms of kinase activation in skeletal muscle fibers in relation to phosphorylation of the RLC.
To begin to delineate which ER in skeletal muscle triggers events that phosphorylate the RLC, we used specific siRNA to knock down each ER in C 2 C 12 cells. Results of these experiments demonstrate that pRLC is mediated through ER␤ and GPER, but not ER␣ (Fig. 5) . This is partially consistent with a study on vascular smooth muscle cells showing that E 2 regulates pRLC by a specific subset of receptors, in this case through GPER and ER␣ (19) . The difference in ER␣ vs. ER␤ inducing pRLC in different muscle types may be due to a number of factors, including different subcellular localization of ERs, expression levels of ERs, and abundance of signaling components specific to smooth vs. skeletal muscle cells. Future efforts to illustrate ER-mediated pRLC in skeletal muscle should initially be focused on ER␤ and GPER based on our siRNA results in C 2 C 12 cells. Also, we previously demonstrated that ERs are expressed in skeletal muscles of OVX mice (2), indicating that reduced kinase signaling is not primarily impacted by the level of ER expression.
MLCK is a key kinase phosphorylating RLC in skeletal muscle (23) . In the present study, the E 2 -induced increases in pRLC and associated force generation occurred through MLCK in both fast-twitch EDL and slow-twitch soleus muscles, because the MLCK inhibitor ML-7 efficiently blunted these effects (Figs. 6 and 7) . Exposure of EDL muscles to E 2 did not affect the inhibition of pRLC and muscle potentiation by ML-7 (Fig. 6) , indicating that the EDL muscle relies on MLCK for E 2 -induced pRLC. However, in soleus muscles, an E 2 -sensitive kinase or kinase pathway, in addition to MLCK, can phosphorylate RLC because E 2 exposure to those muscles increased pRLC and force in the presence of ML-7 (Fig. 7) . This result is not surprising, as genetic deletion of skeletal muscle MLCK in mice only partially abolished pRLC, indicating the presence of other kinases leading to the phosphorylation of RLC, such as the zipper interacting protein kinase (23, 59) . The discrepancy between EDL and soleus muscles in the reliance of MLCK on E 2 -induced pRLC could be related to different abundances of MLCK and myosin light chain phosphatase proteins and their activities in the two muscles (50), differences in cellular context for ER-mediated signaling pathways, or myosin isoform differences between the two muscles. In regard to the latter, there is fiber type heterogeneity in the mouse soleus muscle as is it comprised of type I and IIa fibers based on myosin heavy chain isoform expressions (13) , whereas mouse EDL muscle is more homogeneous, with only type II fibers (52) , and it has been demonstrated that potentiation is greater in type II than in type I fibers (60) . How the effects of E 2 may differ among fibers with various isoforms of the myosin heavy and light chains is not presently clear, nor is the impact of estrogen status on expression of the various myosin isoforms. There are reports of OVX-related shifts toward slower isoforms/fiber types (11, 22, 42) , toward faster isoforms/fiber types (29, 45, 61) , and no changes in myosin isoforms/fiber types (9, 39, 42, 47, 66) . Importantly, when such shifts are detected they are modest, in the magnitude of 10% or less, and thus likely have little impact on the extent of force potentiation reported here. E 2 activates several kinases and signaling pathways in various skeletal muscle cell lines (4, 8, 48) and skeletal muscle of rodents (32, 56, 68 ). In our screen of E 2 -responsive kinases using a kinase inhibitor library and C 2 C 12 cells, we identified 11 inhibitors that decreased pRLC triggered by E 2 ( Table 1) . The corresponding kinases can be profiled according to known kinase cascades, suggesting that E 2 -mediated phosphorylation of the RLC may be stimulated through the PI3K/MAPK/Akt/ MLCK and CamKII/ROCK kinase pathways (Fig. 8) . Our result that E 2 stimulates the MAPK pathway to phosphorylate the RLC is consistent with results from Hamdi and Mutungi (20) . Similarly, PI3K and Akt are involved in modulating pRLC mediated by E 2 , which is consistent with E 2 -mediated PI3K signaling in smooth muscle contraction (19) . ROCK has been shown to mediate pRLC by decreasing myosin light chain phosphatase activity and/or directly phosphorylating RLC (1, 54, 57, 62) . Our findings demonstrate that inhibition of ROCK led to decreased E 2 -induced pRLC by 26%. Cross-talk among signaling pathways may also play a role in regulating pRLC (34) . For example, it was suggested that cross-talk exists between the tyrosine kinase pathway and the MLCK pathway (21) . By Fig. 8 . Schema depicting cellular signaling pathways that potentially stimulate pRLC in skeletal muscle. On the basis of our results from ML-7 experiments with skeletal muscles and kinase inhibitor screening in C2C12 cells, as well as known kinase cascades as reported in the literature, we propose potential pathways involved in E2-mediated phosphorylation of myosin RLC. All postulated pathways would theoretically start with E2 binding to ER␤ or GPER to activate downstream kinase cascades and culminate in pRLC and enhanced force generation. Src, tyrosine kinase; PI3K, phosphatidylinositide 3-kinases; MAPK, mitogen-activated protein kinase; CamKII, Ca 2ϩ /calmodulin-dependent protein kinase II; Akt, protein kinase B; ERK1/2, extracellular signalregulated kinases; ROCK, Rho-associated protein kinase; MLCK, myosin light chain kinase; RLC, regulatory light chain.
integrating potential RLC kinases from the kinase inhibitor assay into known kinase cascades, the present data suggest that the MAPK, PI3K/Akt, and CamKII cascades are involved in E 2 -induced-phosphorylation of RLC. Furthermore, based on our results with ML-7, it can be inferred that soleus muscle utilizes all of the pathways illustrated, whereas EDL muscle appears to rely solely on those converging on MLCK. Additional experiments are required to substantiate the deduction, particularly in additional muscles composed of various fiber types.
In summary, we provide evidence that skeletal muscle responds to E 2 by modulating phosphorylation of the myosin RLC with functional consequences on contractility. E 2 -stimulated pRLC in skeletal muscle is mediated by several kinases and appears to involve the receptors ER␤ and GPER. The extent to which E 2 influences the phosphorylation of other contractile proteins, such as myosin-binding protein C and troponin I, are important questions yet to be addressed, as most of the kinases we identified for pRLC are not unique to phosphorylation of this protein. What has been determined in this work is that E 2 mediates phosphorylation of RLC and that this appears to be one mechanism by which this hormone exerts its effects on myosin and muscle function. This and additional potential mechanisms are important to elucidate in order to understand the muscle weakness that occurs with hormone deficiency and how those effects translate to longterm functional impact in aging women.
